AccurKardia is an ECG-led diagnostics software company transforming ECGs into a more powerful diagnostic tool and broad biomarker. Our platform AccurECG™, an FDA-cleared Class II SaMD delivering fully automated, near real time ECG interpretation that integrates into clinical workflows. AccurECG™ was named “Best New ECG Technology” (MedTech Breakthrough 2025). Our pipeline includes AK+ Guard™ for hyperkalemia detection from Lead I ECGs (FDA Breakthrough, TAP Dec 2024) and AK-AVS™ for aortic stenosis detection via 12-lead ECGs (FDA Breakthrough Oct 2024). AccurKardia completed Mayo Clinic Platform_Accelerate Cohort 3 and 2024 MedTech Innovator – AHA Heart & Brain Accelerator Track.

Watch Moin Hussaini’s interview at the AHA’s Scientific Sessions 2024 here.